Collegium Pharmaceutical 향후 성장

Future 기준 점검 3/6

Collegium Pharmaceutical 의 수익은 연간 2.4% 감소할 것으로 예상되는 반면, 연간 수익은 36.9% 로 증가할 것으로 예상됩니다. EPS는 연간 21.9% 만큼 성장할 것으로 예상됩니다.

핵심 정보

36.9%

이익 성장률

21.85%

EPS 성장률

Pharmaceuticals 이익 성장	14.4%
매출 성장률	-2.4%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	07 Nov 2025

최근 향후 성장 업데이트

Recent updates

Collegium Pharmaceutical: Another Solid Quarter

Nov 10

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 28% Jump Shows Its Popularity With Investors

Nov 08

We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt

Oct 19

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) P/E Still Appears To Be Reasonable

Jul 31

There May Be Reason For Hope In Collegium Pharmaceutical's (NASDAQ:COLL) Disappointing Earnings

May 16

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Has Caught The Eye Of Investors

Apr 07

Collegium Pharmaceutical: Checking The Boxes

Mar 03

Improved Revenues Required Before Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Find Their Feet

Dec 24

Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion

Nov 26

Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality

Nov 14

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Jul 24

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Jun 05

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

May 13

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

May 10

Collegium Pharmaceutical Q4: The Beat Goes On

Feb 26

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Feb 24

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Jan 05

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Nov 12

이익 및 매출 성장 예측

NasdaqGS:COLL - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	682	N/A	273	254	5
12/31/2026	811	98	355	338	5
12/31/2025	782	78	310	332	5
9/30/2025	757	58	289	291	N/A
6/30/2025	707	36	202	203	N/A
3/31/2025	664	44	197	198	N/A
12/31/2024	631	69	203	205	N/A
9/30/2024	599	89	192	194	N/A
6/30/2024	577	100	276	277	N/A
3/31/2024	567	93	308	309	N/A
12/31/2023	567	48	274	275	N/A
9/30/2023	547	9	266	268	N/A
6/30/2023	537	-11	235	236	N/A
3/31/2023	525	-29	176	177	N/A
12/31/2022	464	-25	123	124	N/A
9/30/2022	362	-43	93	94	N/A
6/30/2022	314	-35	67	69	N/A
3/31/2022	273	43	56	58	N/A
12/31/2021	277	72	102	104	N/A
9/30/2021	326	104	87	90	N/A
6/30/2021	326	107	102	107	N/A
3/31/2021	321	42	115	121	N/A
12/31/2020	310	27	-280	94	N/A
9/30/2020	308	18	-286	87	N/A
6/30/2020	302	0	-313	59	N/A
3/31/2020	299	-13	-341	30	N/A
12/31/2019	297	-23	21	28	N/A
9/30/2019	296	-11	47	54	N/A
6/30/2019	293	-22	N/A	90	N/A
3/31/2019	291	-30	N/A	131	N/A
12/31/2018	280	-39	N/A	169	N/A
9/30/2018	218	-66	N/A	114	N/A
6/30/2018	160	-62	N/A	59	N/A
3/31/2018	90	-70	N/A	-14	N/A
12/31/2017	28	-75	N/A	-67	N/A
9/30/2017	19	-85	N/A	-77	N/A
6/30/2017	7	-98	N/A	-84	N/A
3/31/2017	4	-102	N/A	-87	N/A
12/31/2016	2	-94	N/A	-75	N/A
9/30/2016	0	-76	N/A	-61	N/A
6/30/2016	N/A	-59	N/A	-48	N/A
3/31/2016	N/A	-40	N/A	-31	N/A
12/31/2015	N/A	-20	N/A	-22	N/A
9/30/2015	N/A	-15	N/A	-20	N/A
6/30/2015	N/A	-13	N/A	-18	N/A
3/31/2015	N/A	-12	N/A	-16	N/A

애널리스트 향후 성장 전망

수입 대 저축률: COLL 의 연간 예상 수익 증가율(36.9%)이 saving rate(3.3%)보다 높습니다.

수익 vs 시장: COLL 의 연간 수익(36.9%)이 US 시장(16.2%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: COLL 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: COLL 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -2.4%).

고성장 매출: COLL 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -2.4%).

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: COLL의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/26 00:19
종가	2025/12/26 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Collegium Pharmaceutical, Inc.는 13명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Jenna Davidner	Barclays
Dana Flanders	Guggenheim Securities, LLC
Antonio Arce	H.C. Wainwright & Co.

Collegium Pharmaceutical 향후 성장

Future 기준 점검 3/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 9.1% to US$48.67

Collegium Pharmaceutical, Inc. Raises Guidance for Full Year 2025

Collegium Pharmaceutical, Inc. Raises Earnings Guidance for the Full Year 2025

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Year 2025

Consensus EPS estimates fall by 16%

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year of 2025

Recent updates

Price target increased by 9.1% to US$48.67

Collegium Pharmaceutical: Another Solid Quarter

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 28% Jump Shows Its Popularity With Investors

Executive VP & CFO notifies of intention to sell stock

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Collegium Pharmaceutical, Inc. Raises Guidance for Full Year 2025

Collegium Pharmaceutical, Inc. to Report Q3, 2025 Results on Nov 06, 2025

We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt

Executive VP & Chief Medical Officer recently sold US$672k worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

Independent Director recently sold US$401k worth of stock

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Collegium Pharmaceutical, Inc. Raises Earnings Guidance for the Full Year 2025

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) P/E Still Appears To Be Reasonable

Collegium Pharmaceutical, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) announces an Equity Buyback for $150 million worth of its shares.

Independent Director notifies of intention to sell stock

There May Be Reason For Hope In Collegium Pharmaceutical's (NASDAQ:COLL) Disappointing Earnings

New major risk - Financial position

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Year 2025

Collegium Pharmaceutical, Inc. to Report Q1, 2025 Results on May 08, 2025

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Has Caught The Eye Of Investors

Collegium Pharmaceutical, Inc., Annual General Meeting, May 15, 2025

Insider recently sold US$1.3m worth of stock

Executive VP notifies of intention to sell stock

Consensus EPS estimates fall by 16%

Collegium Pharmaceutical: Checking The Boxes

New minor risk - Earnings quality

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year of 2025

Collegium Pharmaceutical, Inc. to Report Q4, 2024 Results on Feb 27, 2025

Collegium Pharmaceutical, Inc. Appoints Nancy S. Lurker to Its Board of Directors

Executive VP notifies of intention to sell stock

Investor sentiment improves as stock rises 16%

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year 2025

Improved Revenues Required Before Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Find Their Feet

New major risk - Financial position

Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion

Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality

Consensus EPS estimates fall by 22%

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Collegium Pharmaceutical, Inc. Announces Executive Changes, Effective November 12, 2024

Consensus EPS estimates fall by 11%

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Collegium Pharmaceutical, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Executive VP & Chief Medical Officer recently sold US$351k worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

Ironshore Acquisition And Calculated Moves Set To Propel Growth In ADHD Market

Executive VP recently sold US$774k worth of stock

Executive VP notifies of intention to sell stock

Collegium Pharmaceutical, Inc. Updates Financial Guidance for the Full Year 2024

Second quarter 2024 earnings: EPS misses analyst expectations

Collegium Pharmaceutical: Diversifying And Growing

Collegium Pharmaceutical, Inc. Provides Net Product Revenues Guidance for the Second Quarter Ended June 30, 2024; Reaffirms Financial Guidance for the Full Year 2024

Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) agreed to acquire Ironshore Therapeutics Inc. for approximately CAD 550 million.

Collegium Pharmaceutical, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Price target increased by 8.6% to US$41.00

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

New minor risk - Insider selling

Executive VP & Chief Commercial Officer recently sold US$1.1m worth of stock

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 16%

Collegium Announces CEO Transition

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package